ArticleBMJ open2017
Risk of disseminated intravascular coagulation in patients with type 2 diabetes mellitus: retrospective cohort study.
Article in BMJ open, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 17 citations in OpenAlex.
- Trends and disparities in disseminated intravascular coagulation-related mortality among adults aged 25 and above in the U.S., 1999-2020: CDC WONDER insights.Thrombosis journal · 2026Article
- Article
- Effect of Anti-Diabetic Medication Use on Sepsis Risk in Type 2 Diabetes Mellitus: A Multivariate Analysis.Geriatrics (Basel, Switzerland) · 2025Article
- Developmental Impacts of Epigenetics and Metabolism in COVID-19.Journal of developmental biology · 2024Review
- Association Between Nonthyroidal Illness Syndrome and Disseminated Intravascular Coagulation in Sepsis.Journal of inflammation research · 2024Article
- Temporal Trends, Predictors, and Outcomes of Disseminated Intravascular Coagulation in Hospitalizations With Sepsis.Cureus · 2022Article
- PAR2-Induced Tissue Factor Synthesis by Primary Cultures of Human Kidney Tubular Epithelial Cells Is Modified by Glucose Availability.International journal of molecular sciences · 2021Article
- Antithrombotic therapy in diabetes: which, when, and for how long?European heart journal · 2021Review
- Article
- Metabolic Perturbations and Severe COVID-19 Disease: Implication of Molecular Pathways.International journal of endocrinology · 2020Review
- Metformin Use Is Associated With Reduced Mortality in a Diverse Population With COVID-19 and Diabetes.Frontiers in endocrinology · 2020Article
- Real-world evidence on disseminated intravascular coagulation from Japan.Acute medicine & surgeryReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo determine quantitatively the association between type 2 diabetes mellitus (T2DM) and disseminated intravascular coagulation (DIC).
designRetrospective cohort study using a claims database.
settingMedical care institutions representing 9% of all secondary hospitals (acute care hospitals) in Japan.
participantsIn total, 797 324 admissions, comprising 435 354 patients aged 18-79 years at the time of admission, were enrolled between January 2010 and September 2014. All patients were diagnosed with diabetes or admitted to hospitals that provided laboratory data.
main outcome measuresIncidence of DIC reported by physicians in claims data.
resultsLogistic regression analysis found that the risk of DIC was significantly higher in T2DM patients than in non-DM patients (fully adjusted OR: 1.39 (95% CI 1.32 to 1.45)), independent of age, sex, admission year and potential underlying diseases. The higher risk of DIC in T2DM patients was apparent in those who were treated with insulin within the 30-day period prior to admission (1.53 (1.37 to 1.72)). When stratified by the potential underlying diseases, the risk of DIC was higher in T2DM patients with non-septic severe infection (1.67 (1.41 to 1.97)) and with solid tumour (1.59 (1.47 to 1.72)) than in non-DM patients with those underlying diseases. The risk was similar between T2DM and non-DM patients with sepsis (0.98 (0.90 to 1.08)) and lower in T2DM patients with acute leukaemia (0.70 (0.59 to 0.84)).
conclusionsT2DM was associated with a higher risk of DIC, particularly when recently treated with insulin, as well as among admissions with solid tumour or non-septic severe infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.